The announcement coincides with the opening of its new preventative healthcare facility, set to open its doors this summer.
News
AZ’ new headquarters double in price
The initial cost of the building was estimated to be £330m.
J&J announce first-of-its-kind portopulmonary hypertension study results
The findings “Provide important clinical evidence to help inform treatment decisions and fill an unmet need that should benefit patients living with PoPH.”
Roche launches first in vitro lung cancer diagnostic test
The biomarker is the first and only in vitro diagnostic ROS1 immunohistochemistry assay on the market.
Positive results for Novo’s Xultophy
The insulin degludec and liraglutide combination helps patients achieve blood glucose targets.
Sosei Heptares to get $3m Pfizer milestone payment
The deal was initially signed in November 2015 to research and develop potential new medicines directed at up to ten GPCR targets across multiple therapeutic areas.
Novartis’ iscalimab results hint at extended survival of transplanted organs
Currently the average life-span of a transplanted kidney is 12 years for a deceased donor kidney, and about 15 years for a living related transplant.
Just 44% of UK health sector would trust humans over AI
The research surveyed 2,010 UK office workers to unveil what they think about the advances in AI technology.
Biogen completes Nightstar acquisition
The companies announced the acquisition in March this year, with the value estimated at approximately $800 million.
FDA OKs new administration options for GSK’s Nucala
The two new methods, autoinjector and a pre-filled safety syringe, are for patients or caregivers to administer once every four weeks.
Merck, Rigaku to form molecular structure analysis technology collab
The technology will determine the absolute chemical structure of organic molecules and enables X-ray crystallography without crystallisation of the analyte.
Coeliac UK, Innovate UK announce £180K research funding available
Criteria for the projects must underpin and support Coeliac UK’s top ten research priorities.
AZ’ Calquence hits endpoints in late-stage leukemia trial
The success marks the second Calquence pivotal trial in CLL to meet its primary endpoint early.
RCGP responds to new NICE Quality Standard in physical activity
The Royal College of GPs welcomed the ‘pragmatic’ new standard.
Takeda ditches late-stage Ninlaro trial
The company remains “optimistic about Ninlaro and continue to investigate Ninlaro in patient populations across the continuum of multiple myeloma care”.
